Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Tesamorelin: Evidence Summary
Evidence summary for Tesamorelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Tesamorelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| HIV-associated lipodystrophy | Tier A | 5 | FDA-approved indication — reduces trunk fat by 15-18% in pivotal trials |
| Body composition (non-HIV) | Tier B | 3 | Reduces visceral adipose tissue and improves lipid profiles in non-HIV populations |
| Cognitive function (MCI) | Tier C | 1 | Phase II trial showed improved executive function in adults with mild cognitive impairment |
| NAFLD/Fatty liver disease | Tier C | 1 | Limited data showing potential benefit in non-alcoholic fatty liver disease |
References (11)
- Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. . Cureus (2025) PMID: 40510111
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. . AIDS (London, England) (2024) PMID: 38905488
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. . The lancet. HIV (2019) PMID: 31611038
- Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes. . PloS one (2017) PMID: 28617838
- Cardiovascular risk and dyslipidemia among persons living with HIV: a review. . BMC infectious diseases (2017) PMID: 28793863
- Predictors of Treatment Response to Tesamorelin in HIV-Infected Patients with Excess Abdominal Fat. . PloS one (2015) PMID: 26457580
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. . The Annals of pharmacotherapy (2012) PMID: 22298602
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. . Drugs (2011) PMID: 21668043
- Spotlight on tesamorelin in HIV-associated lipodystrophy. . BioDrugs (2011) PMID: 22050344
- Pathogenesis and treatment of HIV lipohypertrophy. . Current opinion in infectious diseases (2011) PMID: 21124215
- Tesamorelin Phase 3 Study 001 for HIV-associated lipodystrophy. . Various (2010) PMID: 21668043